Abstract: An improved method for embedding one or more sensors in SiC is provided. The method includes depositing a binder onto successive layers of a SiC powder feedstock to produce a dimensionally stable green body have a true-sized cavity. A sensor component is then press-fit into the true-sized cavity. Alternatively, the green body is printed around the sensor component. The assembly (the green body and the sensor component) is heated within a chemical vapor infiltration (CVI) chamber for debinding, and a precursor gas is introduced for densifying the SiC matrix material. During infiltration, the sensor component becomes bonded to the densified SiC matrix, the sensor component being selected to be thermodynamically compatible with CVI byproducts at elevated temperatures, including temperatures in excess of 1000° C.

Abstract: A system for predicting vegetation encroachment into a utility asset that includes a remote sensing controller that stores a set of 3D data characterizing a utility asset and vegetation in a digital twin database. The digital twin database stores 3D data characterizing the utility asset and vegetation over time. The system further includes a biomass engine that classifies instances of vegetation characterized by the set 3D data stored in the digital twin database as a particular type of vegetation. The biomass engine further generates a growth curve for each instance of vegetation based on the set of 3D data stored in the digital twin database and the particular type of vegetation. Additionally, the biomass engine predicts future growth for each instance of vegetation based on the growth curve and determines if and when each instance of vegetation will exceed an encroachment threshold associated with the utility asset.

Abstract: The disclosure provides inhibitory RNA polynucleotides that have partial complementarity to a target gene. The inhibitory RNA polynucleotides have at least one mismatched nucleotide and can be designed to increase or decrease the cleavage rate when loaded onto the RNA-induced silencing complex (RISC).

Abstract: Heteroaromatic compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein ring A is: (ii-a), (ii-b), (ii-c), (ii-d), or (ii-e); and wherein n, L, M, U, X, Y, Z, RE, RF, R1, R2A, R2B, R2C, R3, R8, R9 and R10 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts and prodrugs are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts and prodrugs can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Abstract: Compounds of Formula I are described: (I), wherein RP and RQ are defined herein. The compounds transcriptase, the prophylaxis and treatment of infection by HIV, and the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Abstract: Heteroaromatic compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein ring A is: (ii-a), (ii-b), (ii-c), (ii-d), or (ii-e); and wherein n, L, M, U, X, Y, Z, RE, RF, R1, R2A, R2B, R2C, R3, R8, R9 and R10 are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts and prodrugs are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts and prodrugs can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Abstract: In certain embodiments, a method for establishing a communication session includes receiving, from a first endpoint, a request to establish a communication session with a second endpoint. The first endpoint has an associated first security level and is operable to communicate via an IP network, the second endpoint has an associated second security level, and the first security level and the second security level are different. The method further includes determining, based on the first security level associated with the first endpoint and the second security level associated with the second endpoint, a communication session security level. The method further includes determining a communication session path for the requested communication session, the communication session path comprising a media processing module corresponding to the determined communication session security level.

Abstract: Compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein V, W, X, Y, Z, R1, R2, R4, R5, R6, ring A, ring B, j and k are defined herein. The compounds of Formula I, and the pharmaceutically acceptable salts and prodrugs thereof, are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Abstract: N-(Sulfonyloxybiarylmethyl) aminocyclopropanecarboxamide derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

Abstract: A container includes a fan that is reversible so air can be removed from the container as a flexible bag is placed into the container and ambient air can be forced into the container when the flexible bag is being removed from the container. This will facilitate placement and removal of a flexible bag in and from the container.

Abstract: The present invention relates to novel ramipril crystalline particles with improved stability and bioavailability. More particularly, the present invention is directed to individually coated, single ramipril crystalline particles for pharmaceutical and biopharmaceutical applications in oral therapies that are stabilized against decomposition into degradation products, namely, ramipril-DKP and ramipril-diacid, during formulation and storage conditions. The present invention also relates to stabilized ramipril pharmaceutical compositions, novel anhydrous pharmaceutical grade ramipril powders, methods for improving ramipril bioavailability, and methods of manufacture and stabilization of ramipril formulations.

Abstract: Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described. These compounds are inhibitors of HIV integrase and inhibitors of HIV replication, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.

Abstract: Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described. These compounds are inhibitors of HIV integrase and inhibitors of HIV replication, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.